middle.news
Amplia’s Narmafotinib Combo Shows Clear Edge in Pancreatic Cancer Trial
2:31am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Amplia’s Narmafotinib Combo Shows Clear Edge in Pancreatic Cancer Trial
2:31am on Monday 2nd of June, 2025 AEST
Key Points
15 confirmed partial responses achieved in ACCENT Phase 1b/2a trial
Narmafotinib combined with gemcitabine and Abraxane shows superiority over chemotherapy alone
Trial fully recruited with 55 patients enrolled, 21 still ongoing
Drug well tolerated with adverse events comparable to chemotherapy alone
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE